Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action

Overview of attention for article published in Antiviral Research, February 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#10 of 2,849)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 15 X posts from 15 X users, with an upper bound of 17,934 followers.

@canuck_free @rt7683 @jason_willz1 @VigilantFox Here is a drug that’s safe and 100% effective against Ebola and probably Covid but was ignored. https://t.co/3YlaXtb0q8

RT @oslersweb: More good news on Ampligen/rintatolimod's efficacy in preventing severe viral disease. Publication explains drug's activity…

RT @oslersweb: More good news on Ampligen/rintatolimod's efficacy in preventing severe viral disease. Publication explains drug's activity…

RT @oslersweb: More good news on Ampligen/rintatolimod's efficacy in preventing severe viral disease. Publication explains drug's activity…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 11 additional X posts.